Trump’s Prescription Price Promises Have Unraveled Quickly

Statement of Steve Knievel, Advocate, Public Citizen’s Access to Medicines Program

Note: On Monday, a federal judge blocked the Trump administration’s proposal requiring prescription companies disclose list prices in direct-to-consumer advertisements. Wednesday, the Trump Administration withdrew its proposal to require any rebates under Medicare Part D be provided at the point of sale.

Now that two of the administration’s signature drug pricing efforts have come to an end, it’s time to push for real solutions by advancing direct government drug pricing negotiation, stopping price spikes and taking on the monopoly power of prescription drug corporations.